Liquid biopsies to clinical outcomes

This simple blood test can offer a broad range of clinical applications throughout a patient’s treatment cycle.

This liquid biopsy approach has potential clinical utility at many critical decision-making points within a patient's treatment journey, providing oncologists with a platform for regular, non-invasive, and highly-sensitive tumor profiling.

Liquid biopsies can offer a complete picture of tumor heterogeneity and are available when a tissue biopsy is limited or unobtainable.

Find out more about our products
Earlier Diagnosis
Non-invasive
Sensitive analysis
Frequent profiling
Molecular Stratification

Liquid biopsies have been shown to accurately identify tumor-associated mutations from ctDNA in the blood [Gale et al]. In this way, they can help to stratify a tumor in terms of its molecular profile. Improving our understanding of the tumor will ultimately improve the way we treat the patient.

The enhanced eTAm-Seq™ assay was used to analyse ctDNA from the blood samples of 20 NSCLC patients. Data were compared with sequencing data from tissue biopsy samples from the same patients. In the tumor biopsy patient sample, only 40% of tumor biopsies provided sufficient sample for analysis, and in those patients, eTAm-Seq™ reliably detected mutations from the plasma samples, demonstrating 90% concordance with available tissue biopsy samples.

table

Gale, Remon, Lawson, Besse et al. Inivata Ltd; Institute Gustave Roussy IASLC WCLC 2015

Monitoring Treatment Response

When a patient starts a new treatment, liquid biopsy provides a novel way of reviewing the treatment’s effectiveness.

In the example shown here, liquid biopsy was used to monitor the presence of mutations prior to and during treatment.

In the example shown here, the patient was undergoing treatment for Non-Small Cell Lung Cancer.
Liquid Biopsy was used prior to and after treatment, and eTAm-Seq analysis demonstrated that 4 out of 5 mutations were reduced to undetectable levels. In patients who do not respond to treatment, liquid biopsy could be used to more quickly identify when alternative treatment options are required.

Sarah Smalley, Jordi Remon, Davina Gale, Benjamin Besse, et al. Inivata Ltd; Institut Gustave Roussy; AACR-NCI-EORTC 2015

Detecting Disease Relapse

By monitoring ctDNA levels in the blood, it may be possible to track the dynamics of more advanced cancer and identify disease relapse ahead of other methods of detection, such as biomarkers and imaging, as well as measuring risk.

In a recent study by Gale et. al. eTAm Seq’s high sensitivity was able to detect mutations 21 days after treatment.

table2

Gale, Remon, Lawson, Besse et al. Inivata Ltd; Institute Gustave Roussy IASLC WCLC 2015

Tumor Evolution

Liquid biopsy contains ctDNA arising from different sites in the body.

Analysis of ctDNA can detect new mutations early and potentially guide treatment with an alternate targeted therapy.

Liquid biopsies can offer a complete picture of tumor heterogeneity and are available when a tissue biopsy is limited or unobtainable.

In a recent case study, de Novo mutation was identified in a blood sample taken from a patient during relapse, that was not identified when tumor samples were taken from the ovaries during surgery at initial diagnosis (15 months earlier).

On identification of the de Novo mutation, the researchers found that this mutation was, in fact, present within tissue taken from the omentum during surgery. Analysis of liquid biopsy in a clinical setting could have offered the opportunity to adapt treatment earlier.

Forshew Sci Transl Med 2012

Personalized Treatment Plan

When a patient relapses, as a result of residual disease or resistance to treatment, a liquid biopsy offers their physician an opportunity to identify changes in the tumor profile and react quickly and appropriately.